Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Aug 08, 2022
Investor presentation, 8 August 2022
Aug 08, 2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Jul 29, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
Jul 19, 2022
Acadia submits Rett Syndrome New Drug Application to the FDA
Jul 12, 2022
Neuren commences Phase 2 trial of NNZ-2591 in Angelman
Jul 08, 2022
Notification regarding unquoted securities - NEU
Jul 08, 2022
Neuren appoints Chief Medical Officer in United States
May 30, 2022
Results of Meeting
May 30, 2022
AGM Chairman's Address & CEO Presentation
Apr 29, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
Previous
1
2
3
4
Next
